Abstract

Infliximab-Induced Immune Thrombocytopenic Purpura in an Ulcerative Colitis Patient.

Lai, Mark (M);Phan, Timothy (T);Niewiadomski, Ola (O);Ding, Nik (N);

 
     

Author information

Case Rep Gastroenterol.2025 Jun 04;19(1):392-396.doi:10.1159/000545922

Abstract

INTRODUCTION: Ulcerative colitis is a chronic inflammatory disease affecting the colon. Anti-tumor necrosis factor-alpha drugs are a cornerstone of management in ulcerative colitis both in induction and maintenance of remission. Thrombocytopenia is a rare side effect of these drugs.

CASE PRESENTATION: We present a case of infliximab-induced immune thrombocytopenic purpura in a 34-year-old female ulcerative colitis patient.

CONCLUSION: Infliximab can be a cause of drug-induced immune-related thrombocytopenia and patient's platelet counts should be regularly monitored. In patients with severe thrombocytopenia and having been recently commenced on infliximab, prompt referral to hematology specialty is essential.

© Copyright 2013-2025 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.